In a study of 31 DADA2 patients (68), TNF inhibitors significantly reduced the incidence of ischemic events and other vasculitic manifestations but was not effective for immunodeficiency or bone marrow failure, requiring a HSCT. The gene discussed is TNF; the disease is Bone marrow hypocellularity.